Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mustang Bio Inc (MBIO)

Mustang Bio Inc (MBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,920
  • Shares Outstanding, K 12,515
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,600 K
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MBIO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.40
  • Most Recent Earnings $-0.46 on 05/15/24
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -2.00
  • Growth Rate Est. (year over year) +93.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1281 +269.24%
on 06/10/24
1.3000 -63.62%
on 06/18/24
+0.2845 (+150.93%)
since 05/28/24
3-Month
0.1281 +269.24%
on 06/10/24
1.3000 -63.62%
on 06/18/24
-0.5670 (-54.52%)
since 03/28/24
52-Week
0.1281 +269.24%
on 06/10/24
6.2899 -92.48%
on 06/30/23
-5.4370 (-92.00%)
since 06/28/23

Most Recent Stories

More News
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.35 (-2.17%)
MBIO : 0.4730 (+1.59%)
LEGN : 44.29 (-0.83%)
JNJ : 146.16 (+0.25%)
NRIX : 20.87 (+0.63%)
Oncology Market Rising Towards $564.5B Amid Cancer Spike and Biotech Innovations

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before....

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.35 (-2.17%)
MBIO : 0.4730 (+1.59%)
LEGN : 44.29 (-0.83%)
JNJ : 146.16 (+0.25%)
NRIX : 20.87 (+0.63%)
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants...

MBIO : 0.4730 (+1.59%)
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Data from two programs selected for oral presentations at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting and the European...

MBIO : 0.4730 (+1.59%)
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory...

MBIO : 0.4730 (+1.59%)
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to...

MBIO : 0.4730 (+1.59%)
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

Fred Hutch’s Dr. Mazyar Shadman to present data on Mustang’s autologous CAR T-cell therapy for the treatment of B-cell non-Hodgkin lymphomas and chronic...

MBIO : 0.4730 (+1.59%)
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma

MB‐101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) are well tolerated in patients with recurrent GBM in ongoing Phase 1...

MBIO : 0.4730 (+1.59%)
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...

MBIO : 0.4730 (+1.59%)
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...

MBIO : 0.4730 (+1.59%)

Business Summary

Mustang Bio, Inc. a subsidiary of Fortress Biotech, Inc., is a clinical'stage biopharmaceutical company. It focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient's own immune system to eliminate cancer cells. Mustang Bio, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 0.5712
2nd Resistance Point 0.5495
1st Resistance Point 0.5113
Last Price 0.4730
1st Support Level 0.4514
2nd Support Level 0.4297
3rd Support Level 0.3915

See More

52-Week High 6.2899
Fibonacci 61.8% 3.9361
Fibonacci 50% 3.2090
Fibonacci 38.2% 2.4819
Last Price 0.4730
52-Week Low 0.1281

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar